Showing posts with label interleukin-2. Show all posts
Showing posts with label interleukin-2. Show all posts
Sunday, November 14, 2010
Friday, January 22, 2010
Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study
"Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years."
Subscribe to:
Posts
(
Atom
)
